PART 1:
1. To explore the safety of ZG005 in combination with Gecacitinib in patients with relapsed or refractory lymphoma. 2. To determine the recommended Phase II dosing regimen for relapsed or refractory lymphoma.
PART 2:
To evaluate the efficacy of ZG005 in combination with Gecacitinib in patients with relapsed or refractory lymphoma.
Fully understand this study and voluntarily sign the ICF；
Age ≥18 at ICF signing, regardless of gender；
Histologically confirmed relapsed or refractory lymphoma.
Lymphoma with known CNS involvement；
Severe cardiovascular/cerebrovascular diseases.
Any other reason deeming the participant unsuitable for the study, as judged by the investigator.